Optimizing arginine deprivation for hard-to-treat cancers

por Khadeir, Ramsay, Szyszko, Teresa, Szlosarek, Peter W.
Publicado 2017

Bench-to-Bedside Studies of Arginine Deprivation in Cancer

por Field, George C., Pavlyk, Iuliia, Szlosarek, Peter W.
Publicado 2023

Targeting Arginine-Dependent Cancers with Arginine-Degrading Enzymes: Opportunities and Challenges

por Phillips, Melissa M., Sheaff, Michael T., Szlosarek, Peter W.
Publicado 2013

Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy

por Carpentier, Joséphine, Pavlyk, Iuliia, Mukherjee, Uma, Hall, Peter E, Szlosarek, Peter W
Publicado 2022

Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma

por Karydis, Ioannis, Chan, Pui Ying, Wheater, Matthew, Arriola, Edurne, Szlosarek, Peter W., Ottensmeier, Christian H.
Publicado 2016

Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20)

por Burrows, Natalie, Cane, Gaelle, Robson, Mathew, Gaude, Edoardo, J. Howat, William, Szlosarek, Peter W., Pedley, R. Barbara, Frezza, Christian, Ashcroft, Margaret, Maxwell, Patrick H.
Publicado 2016

Role of 3'-Deoxy-3'-[(18)F] Fluorothymidine Positron Emission Tomography-Computed Tomography as a Predictive Biomarker in Argininosuccinate Synthetase 1-Deficient Thoracic Cancers...

por Szyszko, Teresa A., Dunn, Joel T., Phillips, Melissa M., Bomalaski, John, Sheaff, Michael T., Ellis, Steve, Pike, Lucy, Goh, Vicky, Cook, Gary J.R., Szlosarek, Peter W.
Publicado 2022

A Phase 1 study of ADI‐PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1‐negative metastatic uveal melanoma

por Chan, Pui Ying, Phillips, Melissa M., Ellis, Stephen, Johnston, Amanda, Feng, Xiaoxing, Arora, Amit, Hay, Gordon, Cohen, Victoria M. L., Sagoo, Mandeep S., Bomalaski, John S., Sheaff, Michael T., Szlosarek, Peter W.
Publicado 2022

Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mech...

por Szlosarek, Peter W., Phillips, Melissa M., Pavlyk, Iuliia, Steele, Jeremy, Shamash, Jonathan, Spicer, James, Kumar, Sanjeev, Pacey, Simon, Feng, Xiaoxing, Johnston, Amanda, Bomalaski, John, Moir, Graeme, Lau, Kelvin, Ellis, Stephen, Sheaff, Michael
Publicado 2020

Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma

por Phillips, Melissa M., Pavlyk, Iuliia, Allen, Michael, Ghazaly, Essam, Cutts, Rosalind, Carpentier, Josephine, Berry, Joe Scott, Nattress, Callum, Feng, Shenghui, Hallden, Gunnel, Chelala, Claude, Bomalaski, John, Steele, Jeremy, Sheaff, Michael, Balkwill, Frances, Szlosarek, Peter W.
Publicado 2023

A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma

por Phillips, Melissa M., Pavlyk, Iuliia, Allen, Michael, Ghazaly, Essam, Cutts, Rosalind, Carpentier, Josephine, Berry, Joe Scott, Nattress, Callum, Feng, Shenghui, Hallden, Gunnel, Chelala, Claude, Bomalaski, John, Steele, Jeremy, Sheaff, Michael, Balkwill, Frances, Szlosarek, Peter W.
Publicado 2023

BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification

por Barnett, Sarah E., Kenyani, Jenna, Tripari, Martina, Butt, Zohra, Grosman, Rudi, Querques, Francesca, Shaw, Liam, Silva, Luisa C., Goate, Zoe, Marciniak, Stefan J., Rassl, Doris M., Jackson, Richard, Lian, Lu-Yun, Szlosarek, Peter W., Sacco, Joseph J., Coulson, Judy M.
Publicado 2023

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers

por Beddowes, Emma, Spicer, James, Chan, Pui Ying, Khadeir, Ramsay, Corbacho, Javier Garcia, Repana, Dimitra, Steele, Jeremy P., Schmid, Peter, Szyszko, Teresa, Cook, Gary, Diaz, Monica, Feng, Xiaoxing, Johnston, Amanda, Thomson, Jim, Sheaff, Michael, Wu, Bor-Wen, Bomalaski, John, Pacey, Simon, Szlosarek, Peter W.
Publicado 2017

Phase 1, pharmacogenomic, dose‐expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1‐deficient non‐squamous non‐small cell lung cancer

por Szlosarek, Peter W., Wimalasingham, Akhila G., Phillips, Melissa M., Hall, Peter E., Chan, Pui Ying, Conibear, John, Lim, Louise, Rashid, Sukaina, Steele, Jeremy, Wells, Paula, Shiu, Chiung‐Fang, Kuo, Chih‐Ling, Feng, Xiaoxing, Johnston, Amanda, Bomalaski, John, Ellis, Stephen, Grantham, Marianne, Sheaff, Michael
Publicado 2021

Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers

por Chang, Kwang-Yu, Chiang, Nai-Jung, Wu, Shang-Yin, Yen, Chia-Jui, Chen, Shang-Hung, Yeh, Yu-Min, Li, Chien-Feng, Feng, Xiaoxing, Wu, Katherine, Johnston, Amanda, Bomalaski, John S., Wu, Bor-Wen, Gao, Jianjun, Subudhi, Sumit K., Kaseb, Ahmed O., Blando, Jorge M., Yadav, Shalini S., Szlosarek, Peter W., Chen, Li-Tzong
Publicado 2021